このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Cybin マネジメント

マネジメント基準チェック /44

Cybin'sの CEO はDoug Drysdaleで、 Nov2020年に任命され、の在任期間は 3.58年です。の年間総報酬はCA$ 834.17Kで、 79.3%給与と20.7%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.005%を直接所有しており、その価値は$ 10.33K 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と3.6年です。

主要情報

Doug Drysdale

最高経営責任者

CA$834.2k

報酬総額

CEO給与比率	79.3%
CEO在任期間	3.6yrs
CEOの所有権	0.005%
経営陣の平均在職期間	3.6yrs
取締役会の平均在任期間	3.6yrs

経営陣の近況

Recent updates

CEO報酬分析

Cybin の収益と比較して、Doug Drysdale の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	n/a	n/a	-CA$70m
Sep 30 2023	n/a	n/a	-CA$51m
Jun 30 2023	n/a	n/a	-CA$49m
Mar 31 2023	CA$834k	CA$662k	-CA$47m
Dec 31 2022	n/a	n/a	-CA$52m
Sep 30 2022	n/a	n/a	-CA$58m
Jun 30 2022	n/a	n/a	-CA$66m
Mar 31 2022	CA$3m	CA$549k	-CA$68m
Dec 31 2021	n/a	n/a	-CA$63m
Sep 30 2021	n/a	n/a	-CA$58m
Jun 30 2021	n/a	n/a	-CA$43m
Mar 31 2021	CA$2m	CA$277k	-CA$32m

報酬と市場: Dougの総報酬 ($USD 608.10K ) は、 US市場 ($USD 1.58M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Dougの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Doug Drysdale (54 yo)

3.6yrs

在職期間

CA$834,173

報酬

Mr. Douglas L. Drysdale, also known as Doug, is Chief Executive Officer at Cybin, Inc. since November 05, 2020. Mr. Drysdale serves as the Member of Board of Directors for SpineThera, Inc. from May 2022. H...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Eric So	Co-Founder	3.6yrs	CA$624.00k	1.52% CA$ 3.1m
Douglas Drysdale	Chief Executive Officer	3.6yrs	CA$834.17k	0.0050% CA$ 10.3k
Paul Glavine	Co-Founder	no data	CA$624.00k	1.38% CA$ 2.9m
Greg Cavers	Chief Financial Officer	3.6yrs	CA$329.20k	0.0053% CA$ 10.9k
Aaron Bartlone	Chief Operating Officer	less than a year	CA$515.53k	0.092% CA$ 190.7k
John Kanakis	Co-Founder	no data	CA$1.49m	データなし
Alex Nivorozhkin	Chief Scientific Officer	3.5yrs	データなし	0.69% CA$ 1.4m
Lori Challenger	Chief Compliance	2.7yrs	データなし	データなし
Gabriel Fahel	Chief Legal Officer & Corporate Secretary	3.6yrs	データなし	0.038% CA$ 78.2k
Sara Somerset	Chief Communications Officers	no data	データなし	データなし
James Andrews	Chief Cultivation & Extraction Officer	no data	データなし	データなし
Domenico Fuoco	Senior Vice President of Scientific Innovation	no data	データなし	データなし

3.6yrs

平均在職期間

48yo

平均年齢

経験豊富な経営陣: CYBNの経営陣は経験豊富であると考えられます ( 3.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Eric So	Co-Founder	3.6yrs	CA$624.00k	1.52% CA$ 3.1m
Paul Glavine	Co-Founder	3.6yrs	CA$624.00k	1.38% CA$ 2.9m
George Tziras	Chief Business Officer & Director	less than a year	データなし	0.17% CA$ 352.2k
Theresa Firestone	Lead Independent Director	2.8yrs	CA$65.00k	0.0053% CA$ 11.0k
Mark Lawson	Independent Director	3.6yrs	CA$50.00k	0.015% CA$ 31.3k
Grant Froese	Independent Director	3.6yrs	CA$50.00k	データなし
Eric Hoskins	Independent Director	3.6yrs	CA$50.00k	0.013% CA$ 27.2k

3.6yrs

平均在職期間

56.5yo

平均年齢

経験豊富なボード: CYBNの取締役会は経験豊富であると考えられます ( 3.6年の平均在任期間)。

Cybin マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development

Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer, Effective July 1, 2023

Cybin Inc., Annual General Meeting, Aug 29, 2023

Cybin Announces Scientific Management Transition

High number of new and inexperienced directors

Independent Director recently bought US$56k worth of stock

Recent updates

Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development

Forecast to breakeven in 2027

Cybin Inc. announced that it has received $150 million in funding from a group of investors

New minor risk - Profitability

Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder

Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Cybin Inc. announced that it expects to receive $150 million in funding from a group of investors

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting

Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

Cybin Inc. has completed a Composite Units Offering in the amount of $30 million.

New major risk - Revenue and earnings growth

Cybin Inc. Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).

New major risk - Shareholder dilution

Cybin Inc. Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder

Cybin Inc. agreed to acquire Small Pharma Inc. (TSXV : DMT) for $23.2 million.

Cybin Inc. Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial

New major risk - Financial position

Cybin Inc. has completed a Composite Units Offering in the amount of $8.25 million.

Cybin Inc. Announces Phase 2 Cohort 5 Dosing Completion of Cyb003 in Major Depressive Disorder

Cybin Inc. Announces Publication of Sponsored Feasibility Study Validating Kernel's Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain

Cybin Inc. Announces the Development of Scalable Psychedelic Facilitation Training Program, Embarkct

New minor risk - Share price stability

Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer, Effective July 1, 2023

Cybin Inc., Annual General Meeting, Aug 29, 2023

Cybin Announces Scientific Management Transition

Cybin Inc. announced that it expects to receive CAD 41 million in funding from Lincoln Park Capital, LLC

Cybin Inc. Initiates First-In-Human Dosing of CYB004 in Phase 1 Clinical Trial

Cybin Inc. Announces Last Subject Dosed in Part B of Its Phase 1 CYB004-E Trial

Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004

Cybin Inc. Announces Promising Results from Sponsored Kernel Flow Feasibility Study Measuring Psychedelic Effects on the Brain

Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004

Cybin Inc. Outlines Upcoming Priorities and Milestones for Its Clinical Development Programs

High number of new and inexperienced directors

Cybin Inc. Provides Progress Update on Its Cyb004-E Phase 1 Trial

Cybin Achieves Research and Development Milestones Ahead of Projected Timelines

Cybin Inc. Announces First Participants Dosed in Its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder

Cybin Inc. and Clinilabs Drug Development Corporation Announces U.S. Drug Enforcement Agency Grant A Schedule I License to Support the First-In-Human Phase 1/2A Clinical Trial of CYB003

Cybin Inc. Announces Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2A Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Independent Director recently bought US$56k worth of stock

Cybin Inc. Receives Fda Ind Clearance for Its Phase 1/2A Clinical Trial Evaluating Cyb003 for the Potential Treatment of Major Depressive Disorder

Cybin Inc., Annual General Meeting, Aug 15, 2022

Cybin Receives Institutional Review Board Approval for Its Phase 1/2A Clinical Trial Evaluating Cyb003 for the Treatment of Major Depressive Disorder

Cybin Acquires DMT Clinical Study from Entheon Biomedical

Cybin Inc. Submits IND Application to FDA for its Phase 1/2a First-In-Human Trial of CYB003 for Treatment of Major Depressive Disorder

Cybin and Kernel Announce Results from Kernel Flow Piloting of Feasibility Study Measuring Ketamine's Effects on the Brain

Cybin Inc. Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine

High number of new and inexperienced directors

Cybin Inc. Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

High number of new and inexperienced directors

Cybin Announces Successful Completion of in Vivo Preclinical Studies for Its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial

Cybin Inc. to Report Q3, 2022 Results on Feb 10, 2022

Institutional Review Board Grants Approval for Cybin Inc.'s Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for A Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing Covid-Related Distress

Chief Operating Officer recently bought US$97k worth of stock

Cybin Awards Grant for Psychedelic Treatment Clinic At Lenox Hill Hospital to Benefit Underserved Communities

Chief Legal Officer recently bought US$54k worth of stock

Cybin Files Two Additional International Patent Applications in Support of the Company’S Research Phase Programs

Cybin Inc. Deleted from Other OTC

Cybin Files its 13th Patent Application

Cybin Announces Completion of Its 51St Pre-Clinical Psychedelic Molecule Study

Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy

Cybin Inc. Files an International Patent Application Further Strengthening Its Psychedelic Derivative Drug Development Candidates Across 153 Global Jurisdictions

Cybin Inc. Files Its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms

Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder

マネジメント基準チェック /44